Kosan BioSciences -- KOSN | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Kosan BioSciences -- KOSN

An SI Board Since May 2001

Posts	SubjectMarks	Bans	Symbol
933	40	0	KOSN

Emcee: tuck	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
158	one session at EORTC-NCI-AACR, haven't looked at it much yet....... <pre	scaram(o)uche	-	10/14/2002
157	Just saw some volume in KOSN. Of course, you probably saw it, too. eom Cheers,	tuck	-	10/10/2002
156	Biotechnol Prog 2002 Oct 4;18(5):913-920 Control of Secondary Metabolite Conge	scaram(o)uche	-	10/5/2002
155	Oops - wrong thread. That post was of course meant for the ITMN thread. Peter	Biomaven	-	10/1/2002
154	Here's some evidence that lung function tests don't predict mortality in	Biomaven	-	9/30/2002
153	Forbes article on recent Roche deals with early stage biotech (cf also DCGN) -	nigel bates	-	9/30/2002
152	>>The way this game is usually played the pharma (here Roche) has a clause	keokalani'nui	-	9/26/2002
151	Wilder, The way this game is usually played the pharma (here Roche) has a claus	Biomaven	-	9/26/2002
150	Does AH follow Roche and dna? Or even better, have a banking relationship? Hon	keokalani'nui	-	9/26/2002
149	Ooooooooooooooooooooh, wouldn't that be sweet! Wouldn't surprise me. I	scaram(o)uche	-	9/26/2002
148	I hope Adam's Harkness analyst has it right: <<and a sliding scale	rkrw	-	9/26/2002
147	<i>You missed the last sentence.</i> I think 'Cheers, Tuck'	nigel bates	-	9/25/2002
146	while I agree with Steve's "this market" conservatism and comments	scaram(o)uche	-	9/25/2002
145	You missed the last sentence. "And that's all there is to it."	keokalani'nui	-	9/25/2002
144	>>Antimicrob Agents Chemother 2002 Sep;46(9):2772-8 Heterologous Express	tuck	-	9/25/2002
143	<i>Here are the titles: "Synthesis and Antibacterial Activity of C6-	scaram(o)uche	-	9/25/2002
142	Wilder, Y'all are welcome. I've got to get bolder about calling small	tuck	-	9/25/2002
141	Yes, thank you, tuck. Of course, re. wildest's comment, jnj has a well esta	quidditch	-	9/25/2002
140	Bravo, Tuck. Thank you. The good news is that the imminent announcement does n	keokalani'nui	-	9/25/2002
139	Miscellaneous rambling . . . The PII versus commercial production figures	tuck	-	9/25/2002
138	>> some sort of barter deal using Meiji bugs could be worked out that coul	scaram(o)uche	-	9/24/2002
137	Called the company today and talked to Mr. Ostrach. Having looked at the questi	tuck	-	9/24/2002
136	Wilder, <i>why no mention of manufacturing responsibility (or revenue opp	Biomaven	-	9/24/2002
135	Quid >>especially re. the JNJ program and the mystery further announcemen	keokalani'nui	-	9/24/2002
134	And, in terms of the buy-in option, clarification that KOSN's obligation to	quidditch	-	9/24/2002

Go to reply# or date (mm/dd/yy):